ATE192655T1 - Verwendung von histamin-gamma-globulin zur herstellung eines immunomodulierenden und antiinflammatorischen agens - Google Patents

Verwendung von histamin-gamma-globulin zur herstellung eines immunomodulierenden und antiinflammatorischen agens

Info

Publication number
ATE192655T1
ATE192655T1 AT94112427T AT94112427T ATE192655T1 AT E192655 T1 ATE192655 T1 AT E192655T1 AT 94112427 T AT94112427 T AT 94112427T AT 94112427 T AT94112427 T AT 94112427T AT E192655 T1 ATE192655 T1 AT E192655T1
Authority
AT
Austria
Prior art keywords
agent
diseases
histamine
pharmaceutical composition
immunomodulating
Prior art date
Application number
AT94112427T
Other languages
English (en)
Inventor
Haruo Yoshii
Yuriko Fukata
Original Assignee
Nippon Zoki Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co filed Critical Nippon Zoki Pharmaceutical Co
Application granted granted Critical
Publication of ATE192655T1 publication Critical patent/ATE192655T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94112427T 1993-08-09 1994-08-09 Verwendung von histamin-gamma-globulin zur herstellung eines immunomodulierenden und antiinflammatorischen agens ATE192655T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21804393A JP3193205B2 (ja) 1993-08-09 1993-08-09 好酸球増多抑制剤

Publications (1)

Publication Number Publication Date
ATE192655T1 true ATE192655T1 (de) 2000-05-15

Family

ID=16713756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94112427T ATE192655T1 (de) 1993-08-09 1994-08-09 Verwendung von histamin-gamma-globulin zur herstellung eines immunomodulierenden und antiinflammatorischen agens

Country Status (9)

Country Link
US (1) US5780026A (de)
EP (1) EP0646376B1 (de)
JP (1) JP3193205B2 (de)
KR (1) KR100275174B1 (de)
CN (3) CN1127983C (de)
AT (1) ATE192655T1 (de)
DE (1) DE69424362T2 (de)
ES (1) ES2146240T3 (de)
TW (1) TW258664B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
US6566386B2 (en) 1993-08-09 2003-05-20 Nippon Zoki Pharmaceutical Co., Ltd. Immunomodulating and antiinflammatory agent
IT1278052B1 (it) * 1995-03-14 1997-11-17 Mendes Srl Uso delle immunoglobuline della classe g, in particolare delle immunoglobuline per uso endovenoso o per uso intramuscolare, per
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
JPH0959180A (ja) 1995-08-11 1997-03-04 Nippon Zoki Pharmaceut Co Ltd 活性化免疫グロブリン
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
JPH10212246A (ja) 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
JP2000143536A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 抗浮腫剤
JP2000143537A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 細胞接着分子発現抑制剤
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE19944122A1 (de) * 1999-09-15 2001-03-29 Wolfgang Loh Histamin-Immunglobulin-Komplexe zur Behandlung von entzündlichen Erkrankungen bei Säugetieren
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
WO2004075845A2 (en) * 2003-02-24 2004-09-10 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2142200B1 (de) * 2007-05-10 2012-05-16 Rajesh Shah Formulierung auf homöopathischer basis
ES2728225T3 (es) 2009-02-20 2019-10-23 2 Bbb Medicines B V Sistema de administración de fármacos a base de glutatión
US8445002B2 (en) 2009-05-06 2013-05-21 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5585526A (en) * 1978-12-23 1980-06-27 Nippon Zoki Pharmaceut Co Ltd Remedy for allergic disease
US4704273A (en) * 1982-05-17 1987-11-03 Mcmichael John Methods and materials for treatment of rheumatoid arthritis
US4705685A (en) * 1982-05-17 1987-11-10 Mcmichael John Methods and materials for treatment of disease states involving immunological factors
US4705687A (en) * 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US5244902A (en) * 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
IT1237475B (it) * 1989-10-06 1993-06-07 Allergeni modificati chimicamente e procedimento per la loro preparazione
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤

Also Published As

Publication number Publication date
DE69424362T2 (de) 2000-10-19
US5780026A (en) 1998-07-14
JP3193205B2 (ja) 2001-07-30
CN1471974A (zh) 2004-02-04
JPH0753406A (ja) 1995-02-28
TW258664B (de) 1995-10-01
KR950005323A (ko) 1995-03-20
KR100275174B1 (ko) 2000-12-15
CN1127983C (zh) 2003-11-19
CN1121430A (zh) 1996-05-01
EP0646376B1 (de) 2000-05-10
DE69424362D1 (de) 2000-06-15
EP0646376A1 (de) 1995-04-05
ES2146240T3 (es) 2000-08-01
CN1471975A (zh) 2004-02-04

Similar Documents

Publication Publication Date Title
ATE192655T1 (de) Verwendung von histamin-gamma-globulin zur herstellung eines immunomodulierenden und antiinflammatorischen agens
MY131458A (en) Pyrolopyrimidine compounds
NL300224I1 (nl) 3-Benzazepinzonen gesubstitueerd met een benzocyclobutyl-of indanylalkyla-minoalkylgroep, bruikbaar voor de behandeling van cardiovasculaire aandoeningen.
HU9303458D0 (en) Process for producing sulfonamides and pharmaceutical preparations containing them
DE59310085D1 (de) Indolocarbazol-imide und deren verwendung
FI931370A0 (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
FI950697A0 (fi) IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan
IT1091051B (it) Procedimento per l'estrusione ad alta riduzione di metalli
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
GR3031149T3 (en) Process for the manufacture of (s)-3-amino-1-substituted-pyrrolidines.
DE69813070T2 (de) Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex
DE59404784D1 (de) Neue carbonsäureester von 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purin, deren herstellung sowie deren verwendung
EP0459176A3 (en) Oligophosphates with antiviral activity
ZA895710B (en) The use of imexon as immune suppressive and pharmaceutical compositions containing imexon
GB2132620B (en) Novel 6a-methylprednisolone derivatives and their manufacture and use
IT1254745B (it) Ciclofosfazeni contenenti gruppi di acido acetil salicilico, procedimento di preparazione ed utilizzazione

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee